| First author, year | Sample size (T/C) | Population characteristics | Treatment | Control | Duration of treatment | Follow-up | Outcome assessment |
| Gao, 2016 [10] | 100 (50/50) | T: mean age (51.32 years) M/F (28/22 cases) C: mean age (51.16 years) M/F (24/26 cases) | TMXKT 0.24 g/time, Bid + control | Metformin 0.5 g/time, Tid | 3 months | None | FPG 2HPG HbA1c |
| Huang, 2016 [11] | 86 (42/44) | T: mean age (NA) M/F (18/24 cases) C: mean age (NA) M/F (21/23 cases) | TMXKT 0.24 g/time, Bid + control | Metformin 0.5 g/time, Tid | 12 weeks | None | FPG 2HPG HbA1c BMI |
| Liang, 2014 [12] | 134 (69/65) | T: mean age (52 years) M/F (32/37 cases) C: mean age (56 years) M/F (29/36 cases) | TMXKT 0.24 g/time, Bid + control | Metformin 0.5 g/time, Tid | 12 weeks | None | FPG 2HPG HbA1c |
| Shao, 2017 [13] | 80 (40/40) | T: mean age (NA) M/F (NA) C: mean age (NA) M/F (NA) | TMXKT 0.24 g/time, Bid + control | Metformin 0.5 g/time, Bid | 12 weeks | None | FPG 2HPG HbA1c |
| Yuan, 2011 [14] | 120 (60/60) | T: mean age (NA) M/F (36/24 cases) C: mean age (NA) M/F (34/26 cases) | TMXKT 0.24 g/time, Bid + Metformin 0.25 g/time, Tid | Metformin 0.5 g/time, Tid | 3 months | None | FPG 2HPG HbA1c BMI |
| Shi, 2015 [15] | 105 (53/52) | T: mean age (NA) M/F (36/24 cases) C: mean age (NA) M/F (34/26 cases) | TMXKT 0.24 g/time, Bid + control | Aspart insulin 30 12–16 U/time, Bid | 16 weeks | None | FPG 2HPG HbA1c BMI |
| Tan, 2015 [16] | 92 (46/46) | T: mean age (50.18 years) M/F (33/13 cases) C: mean age (49.82 years) M/F (34/12 cases) | TMXKT 0.24 g/time, Bid + control | Pioglitazone, 15 mg/time Bid | 8 weeks | None | FPG |
|
|
BMI, body mass index; FPG, fasting blood glucose; HbA1c, glycosylated hemoglobin A1c; 2HPG, 2-h postprandial blood glucose; TMXKT, Tianmai Xiaoke tablet.
|